GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (CHIX:OBSNz) » Definitions » Short Interest

ObsEva (CHIX:OBSNZ) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is ObsEva Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of ObsEva's Short Interest

For the Biotechnology subindustry, ObsEva's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ObsEva's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's Short Interest distribution charts can be found below:

* The bar in red indicates where ObsEva's Short Interest falls into.


ObsEva (CHIX:OBSNZ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (CHIX:OBSNz) » Definitions » Short Interest
Comparable Companies
XSWX:ADXN XSWX:SPEX XSWX:KNRS XSWX:EVE XSWX:RLF OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270
Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
Website
https://www.obseva.com
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva (CHIX:OBSNZ) Headlines

No Headlines